

Monthly Factsheet - August 2024

# A sub-fund of Amundi Asia Funds

# Key Information (Source: Amundi)

Net Asset Value (NAV)	135.54 (USD)
Inception date	30/09/2022
Share-class reference currency	USD
Sub-fund reference currency	USD
NAV and AUM as of	30/08/2024
Assets Under Management (AUM)	87.85 (million USD
Maximum management fees	0.95%
Total Expense Ratio	1.37 (realized) - 22/12/2023
Registered country	Luxembourg
ISIN code	LU2485621705
Bloomberg code	AASCIAD LX
Benchmark	None

# Investment Objective and Strategy

The Fund seeks to achieve growth mainly through capital appreciation over a mid to long-term investment horizon.

The Fund is managed by Amundi, combining topdown macroeconomic views and bottom-up mutual funds and ETFs selection from Standard Chartered's Chief Investment Office (CIO) and Managed Investments Team.

# Risk Indicator (Source : Fund Admin)




The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

# **Returns (Source: Fund Admin)**





# Cumulative returns (Source: Fund Admin)

Since	<b>YTD</b> 28/12/2023	1 month 31/07/2024	<b>3 months</b> 31/05/2024	6 months 29/02/2024	<b>1 year</b> 31/08/2023	<b>Since</b> 30/09/2022
Portfolio	11.94%	1.56%	5.86%	9.09%	18.08%	35.54%
<b>0</b> - 1 - 1 - 1 - 1 - 1 - 1 - 1		* /O E				
Calendar ye	ear performanc	e * (Source: F	und Admin)			
Calendar ye	ear performanc	e * (Source: F 2023	und Admin) 2022	2021	2020	2019

\* Source: Fund Admin. The above results pertain to full 12-month period per calendar year. All performances are calculated net income reinvested and net of all charges taken by the Sub-Fund and expressed with the round-off superior. The value of investments may vary upwards or downwards according to market conditions.





### Fund statistics (Source: Amundi)


Number of Securities Held	25
Portfolio Volatility	9.82%
Worst Month	09/2023
Best Month	11/2023
Portfolio Sharpe Ratio	1.24
Maximum Drawdown	-6.30%
Data as of end August 2024 (These numbers are over a one yea period)	r




Monthly Factsheet - August 2024


A sub-fund of Amundi Asia Funds








# Allocation to Funds vs ETFs (Source: Amundi)



# Equity breakdown (Source: Amundi)









Monthly Factsheet - August 2024

### A sub-fund of Amundi Asia Funds

	AU (C)	AHK (C)	AS HGD (C)	ZU (C)
Characteristics				
Share class currency	USD	HKD	SGD	USD
Share class category	Accumulation	Accumulation	Accumulation	Accumulation
Dividend frequency	-	-	-	-
NAV per unit	135.54	131.45	117.57	116.01
Inception date	30/09/2022	07/10/2022	18/01/2023	28/07/2023
ISIN code	LU2485621705	LU2485621960	LU2485621887	LU2627318558
Bloomberg Code	AASCIAD LX	AASGIAD LX	AASIGND LX	SGCIZUC LX
Dividend per share	-	-	-	-
Last Dividend Date	-	-	-	-
Bid to Bid returns				
1 month	1.56%	1.40%	1.38%	1.62%
3 months	5.86%	5.54%	5.33%	6.05%
6 months	9.09%	8.69%	8.03%	9.48%
1 year	18.08%	17.45%	15.73%	18.94%
3 years	-	-	-	-
5 years	-	-	-	-
Since Inception	17.18%	16.28%	10.73%	14.11%
Offer to Bid returns *				
1 month	-3.28%	-3.42%	-3.45%	1.62%
3 months	0.82%	0.51%	0.31%	6.05%
6 months	3.89%	3.51%	2.89%	9.48%
1 year	12.45%	11.86%	10.22%	18.94%
3 years	-	-	-	-
5 years	-	-	-	-
Since Inception	14.24%	13.33%	7.44%	14.11%

Annualised returns for periods exceeding 1 year (365 days basis). Returns are computed on the assumption that all dividends and distributions are reinvested, taking into account all charges which would have been payable upon such reinvestment.

\* Offer to Bid returns include an assumed sales charge of 5%, which may or may not be charged to investors.

### List of shareclass

NAME	AUM	CURRENCY	ISIN	BLOOMBERG	INCEPTION DATE	NAV	HGD / UNHGD	CATEGORY	Monthly Dividend	Dividend Yield Annual
AU	40.85 M	USD	LU2485621705	AASCIAD LX	30/09/2022	135.54	Unhgd	Acc.	-	-
SC Invest HK	7.8 K	HKD	LU2840098516	SIGCGSC LX	17/07/2024	100.03	Unhgd	Acc.	-	-
AHK	14.26 M	HKD	LU2485621960	AASGIAD LX	07/10/2022	131.45	Unhgd	Acc.	-	-
AE HGD	0.21 M	EUR	LU2627314995	SGCIAEH LX	29/02/2024	108.2	Hgd	Acc.	-	-
ZU	25.89 M	USD	LU2627318558	SGCIZUC LX	28/07/2023	116.01	Unhgd	Acc.	-	-
AS HGD	17.64 M	SGD	LU2485621887	AASIGND LX	18/01/2023	117.57	Hgd	Acc.	-	-
I1U	3.47 M	USD	LU2708337568	SICRIUC LX	21/05/2024	104.32	Unhgd	Acc.	-	-
SC Invest S	0.03 M	SGD	LU2840098359	SIGCRSC LX	17/07/2024	96.97	Unhgd	Acc.	-	-
SC Invest HK MD	7.8 K	HKD	LU2840098607	SIGCGSH LX	17/07/2024	99.78	Unhgd	Dist.	0.25	3.12%
AU MD	0.48 M	USD	LU2627315539	SGGRAUM LX	22/03/2024	104.61	Unhgd	Dist.	0.25	2.98%
SC Invest S MD	1.3 K	SGD	LU2840098433	SIGCGMD LX	17/07/2024	96.73	Unhgd	Dist.	0.25	3.15%
AE HGD MD	0.64 M	EUR	LU2627314649	SGAEHDM LX	04/04/2024	104.25	Hgd	Dist.	0.25	2.99%
AS HGD MD	1.21 M	SGD	LU2627313328	SIGASHD LX	27/03/2024	104.12	Hgd	Dist.	0.25	2.99%
AHK MD	7.8 K	HKD	LU2627314219	SIGAHMD LX	17/07/2024	99.78	Unhgd	Dist.	0.25	3.12%







Monthly Factsheet – August 2024

A sub-fund of Amundi Asia Funds

### Investment adviser commentary

#### Market Review

August concluded on a positive month for the markets, with equities rebounding quickly from early month lows when investors were jittery over a slew of cooling labour data, alongside mixed mega cap earnings over the past week. Mounting geopolitical tensions in the Middle East likely exacerbated the down move.

Despite these initial setbacks, the US economy showed resilience as global equities and other risk assets extended their recovery amid fresh economic data which restored confidence in the market. Fed Chair Powell's speech at the Jackson Hole Symposium reinforced the likelihood of a rate cut in September. Rate cut hopes have lowered US bond yields and the US dollar. This resulted in the 10-year and 2-year government bond yields closing the month at 3.91% and 3.92%, respectively. Major indices posted gains for the month, which positively impacted portfolio performance.

While we expect a soft landing in the US economy, focus on the US election is increasing and the geopolitical situation remains fragile. Looking forward, uncertainty is likely to remain elevated.

#### Fund Performance

The Signature CIO Growth fund posted positive returns in August. Within equities, US equities were standout performers, bolstered by increased confidence in a potential soft landing for the US economy, which fuelled a rebound in risk assets. Europe-ex UK equity also performed strongly as a significant drop in euro zone inflation cemented market expectations for ECB to cut interest rates in September.

Within fixed income, US government bond yields declined following dovish statements from the Fed. This led to positive returns across the asset class due to rising expectations of upcoming rate cuts in both Europe and the US. Developed Market (DM) Investment Grade (IG) Government bonds saw solid price gains, contributing positively to the portfolio. Similarly, DM IG corporate bonds have added to performance, supported by stable fundamentals and a favourable earnings outlook. Additionally, a weaker US dollar and declining yields further bolstered returns for emerging market bonds.

Gold was another notable contributor to the fund's positive performance, with prices continuing to rise amid subdued interest rates and a weaker US dollar.

#### Fund Positioning

Following our Global Investment Committee's (GIC) decision to downgrade equities to a neutral stance, we have reduced the overall equity allocation across all portfolios. Markets appeared to have priced in for our central scenario of a soft landing. However, with the US elections approaching, there is potential for increased market volatility.

We have trimmed some exposure from US equities, taking profit from the recent rally. Nevertheless, over the next 6 to 12 months, US equities remain our most preferred equity region, maintaining a higher weighting than our Strategic Asset Allocation (SAA) model. US companies continue to show strong long-term earnings growth, and recent market volatility provides pockets of opportunities in the growth sectors, particularly in areas related to artificial intelligence (AI).

As the GIC downgraded Europe ex-UK equities to underweight, we have reduced our exposure to the region. Growth expectations in the Euro area have softened following last year's upturn. Additionally, Europe's indirect exposure to China's economic weakness and potential tariffs if a Trump administration were to return could pose short-term headwinds for European equities.

Conversely, we have increased our allocation to UK equities, driven by improving activity data and the prospect of a pro-business Labour government, which we see as positive catalysts for the region.

Within bonds, we continue to favour Emerging Market (EM) USD government bonds, maintaining a higher allocation relative to our SAA model. This asset class remains more sensitive to changes in yields, and current spreads relative to historical spreads are wider than in other credit markets.

Additionally, we have added a small allocation to EM local currency government bonds with anticipation that a weaker U.S. dollar will benefit this asset class as the Fed embarks on the rate cut cycle.

We have also closed our positions in floating rate notes and reallocated to developed market (DM) investment-grade (IG) corporate bonds to increase the duration within our portfolio. This strategic shift aims to enhance portfolio resilience amid evolving market conditions.

To hedge against market uncertainty, we increased our allocation to gold, which we believe will perform well amid rising political and geopolitical risks in the short term. This is funded by the reduction in global bonds.

Within the opportunistic basket, given the recent price action in the US treasury markets, we took profit and exited the position of US Treasury 1–3-year bonds. Similarly, we also cut the existing holding of US Agency MBS bonds by 1%.

We have initiated a new position in US healthcare equity. Historically, this sector has been among the strongest performers during the early stages of rate-cutting cycles. While earnings in the healthcare sector have declined in recent years, we expect a recovery over the coming quarters.







Monthly Factsheet – August 2024

A sub-fund of Amundi Asia Funds

# Foundation Portfolio - Breakdown of Securities and Asset Classes (Source: Amundi)

	Portfolio	Instrument type (ETF / Fund)
Equities	73.8%	-
North America Equities	46.5%	-
AMUNDI S&P 500 ETF D-USD	9.1%	ETF
VANGUARD S&P 500 ETF USD ACC	8.8%	ETF
XTRACKERS MSCI USA ETF 1C	8.7%	ETF
ISHARES CORE S&P 500 ETF USD ACC	8.6%	ETF
VANGUARD FTSE NORTH AMERICA UCITS ETF	8.0%	ETF
ISHARES MSCI NORTH AMERICA ETF USD DIST	3.4%	ETF
Asia ex-Japan Equities	10.4%	-
ISHARES CORE MSCI EM IMI ETF USD ACC	4.1%	ETF
ISHARES MSCI EM EX-CHINA UCITS ETF USD A	4.0%	ETF
ISHARES MSCI EM ASIA ETF USD ACC	2.3%	ETF
Europe ex-UK Equities	8.9%	-
ISHARES MSCI EUROPE EX-UK ETF EUR DIST	8.9%	ETF
Japan Equities	5.0%	-
ISHARES CORE MSCI JAPAN IMI ETF USD ACC	5.0%	ETF
UK Equities	3.0%	-
VANGUARD FTSE 100 UCITS ETF	3.0%	ETF
Fixed Income	15.7%	-
DM IG Corporate Bonds	6.2%	-
ISHARES GLOBAL CORP BOND ETF USD H ACC	2.6%	ETF
ISHARES US MORTG BACKED SECS ETF USD DIS	2.0%	ETF
JPM AGGREGATE BOND I ACC USD	1.6%	Fund
DM IG Government Bonds	3.8%	-
ISHARES GLOBAL GOVT BOND UCITS ETF USD H	2.8%	ETF
ISHARES TREASURY BD 7-10YR ETFUSD DIST	1.0%	ETF
EM USD Government Bonds	2.6%	-
PRINCIPAL GI FIN UNCON EM FX INC 12 ACC	2.6%	Fund
Asia USD Bonds	1.5%	-
PIMCO GIS ASIA STRATINTSBD INS USD INC	1.0%	Fund
BGF ASIAN TIGER BOND 13 USD	0.5%	Fund
DWS INVEST ASIAN BONDS USD IC	0.0%	Fund
DM HY Corporate Bonds	1.5%	-
BGF GLOBAL HIGH YIELD BOND I2 USD	1.5%	Fund
Gold	6.3%	-
Gold	6.3%	-
INVESCO PHYSICAL GOLD ETC	6.3%	ETF
Money Market / Cash	2.2%	-
Money Market / Cash	2.2%	-
BNP PARIBAS INSTICASH USD	1.8%	Fund
Cash	0.4%	-
Opportunistic Portfolio - Breakdown of Securities and Asset Class	ses (Source: Amundi)	
	Portfolio	Instrument type (ETF / Fund)
		instrument type (ETF / Fullu)

	Portfolio	Instrument type (ETF / Fund)
Equities	2.0%	-
North America Equities	2.0%	-
ISHARES S&P HEALTH CARE	2.0%	ETF







Monthly Factsheet – August 2024

# A sub-fund of Amundi Asia Funds

# Important and Legal Information

This document contains information about Amundi Asia Funds **Signature CIO Growth Fund** (the "Fund"), a sub-fund of Amundi Asia Funds, an undertaking for collective investment in transferable securities existing under Part I of the Luxembourg law of 17 December 2010, organised as an open-ended mutual investment fund ("fonds commun de placement"). The management company of the Fund is Amundi Luxembourg S.A., 5, allée Scheffer, L-2520 Luxembourg and the Singapore Representative of the Fund is Amundi Singapore Limited (Registration No. 198900774E), 80 Raffles Place, UOB Plaza 1, #23-01, Singapore 048624 (Amundi Luxembourg S.A. and/or its affiliated companies, including without limitation Amundi Singapore Limited, being hereinafter referred to individually or jointly as "Amundi"). Amundi Singapore Limited by the Monetary Authority of Singapore.

This is a marketing communication. Investors should read the Singapore Prospectus and the Product Highlights Sheet before deciding to invest in the Fund. The share classes / classes of the Fund available for offer to the retail public in Singapore are set out in the Singapore Prospectus and the Product Highlights Sheet, which together with the latest annual and semi-annual reports (if any) may be obtained, free of charge, at the registered office of the Singapore Representative of the Fund or at www.amundi.com.sg or the Fund's authorised distributors.

This document is for information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell the Fund in any jurisdiction where such offer, solicitation or invitation would be unlawful. This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any U.S. Person (as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933 and in the Singapore Prospectus of the Fund). The Fund is not registered in the United States under the Investment Company Act of 1940 and shares / units of the Fund are not registered in the United States under the Securities Act of 1933. Accordingly, this document is for distribution or to be used solely in jurisdictions where it is permitted and to persons who may receive it without breaching applicable legal or regulatory requirements, or that would require the registration of Amundi or its affiliates in these countries.

Past performance and any forecasts made are not indicative of future performance of the Fund. Please note that distribution/dividends (if applicable) are not guaranteed unless otherwise stated in the dividend policy for the relevant share class / class contained in the Singapore Prospectus. Investors should review the relevant dividends disclosure report (if applicable) found on www.amundi.com.sg. Any opinion or view presented is subject to change without notice. The information on this document is intended for general circulation without taking into account the specific investment objectives, financial situation or particular needs of any particular investor. An investor may wish to seek advice from a financial adviser regarding the suitability of the Fund, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before making a commitment to purchase shares / units in the Fund.

Where applicable and contemplated in the Singapore Prospectus, the Fund may invest in financial derivatives as part of its strategy, and a material portion of the returns may be generated from financial derivative strategies. In such scenarios, the Fund will be subject to risks associated with such investments as further detailed in the Singapore Prospectus. Additional risk factors are described in the Singapore Prospectus. Investments in the Fund are subject to investment risks, including the possible loss of the principal amount invested. Such activities may not be suitable for everyone. Value of the shares / units in the Fund and the income accruing to the shares / units, if any, may fall or rise. Any forecast, projection or target is indicative only and is not guaranteed in any way. Such information is solely indicative and may be subject to modification from time to time. References to specific securities are presented to illustrate the application of our investment philosophy only and are not to be considered recommendation by Amundi.

It is the responsibility of investors to read the legal documents in force in particular the current Singapore Prospectus of the Fund. Subscriptions in the Fund will only be accepted on the basis of their latest prospectus available in English and/or the Product Highlights Sheet. A summary of information about investors' rights and collective redress mechanisms can be found in English on the regulatory page at https://about.amundi.com/Metanav-Footer/Footer/Quick-Links/Legal-documentation.

Information on sustainability-related aspects (if applicable) can be found at https://about.amundi.com/Metanav-Footer/Quick-Links/Legal-documentation.

The information contained in this document is as at the date of publication of this document except where otherwise stated. The information contained in this document has been obtained from sources believed to be reliable but has not been independently verified, although Amundi and its affiliated companies believe it to be fair and not misleading. Total percentage may not add to 100% due to rounding. Amundi does not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this document. Amundi and its associates, directors, connected parties and/or employees may from time to time have interests and or underwriting commitments in the investments mentioned in this document. Amundi does not guarantee that all risks associated to the transactions mentioned herein have been identified, nor does it provide advice as to whether you should enter into any such transaction. Amundi does not make any representation as to the merits, suitability, expected success, or profitability of any such transaction mentioned herein.

Pursuant to the new Guidelines on marketing communications under Regulation (EU) 2019/1156 of 20 June 2019 on cross-border distribution of funds issued by the European Securities and Markets Authority (ESMA), performance returns which are less than 12 months will not be reported for European domiciled funds.

### This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

The information contained shall not be copied, reproduced, modified, translated or distributed without the prior written approval of Amundi.

### Further Disclaimer relating to Standard Chartered Bank

Standard Chartered Bank is incorporated in England with limited liability by Royal Charter 1853, Reference number ZC 18. The Principal Office of the Company is situated in England at 1 Basinghall Avenue, London, EC2V 5DD. Standard Chartered Bank is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority. Standard Chartered PLC, the ultimate parent company of Standard Chartered Bank, together with its subsidiaries and affiliates (including each branch or representative office), form the Standard Chartered Group. Standard Chartered Private Bank is the private banking division of Standard Chartered. Banking activities may be carried out internationally by different branches, subsidiaries and affiliates within the Standard Chartered Group (collectively "SC" and individually "SC Entity") according to local regulatory requirements. Please contact your Private Banker/Relationship Manager in relation to any matters arising from, or in connection with, this document. Not all products and services are provided by each SC Entity.







Monthly Factsheet – August 2024

A sub-fund of Amundi Asia Funds

# Important and Legal Information

### Singapore

This document is being distributed in Singapore by Standard Chartered Bank (Singapore) Limited (Registration No. 201224747C/GST Group Registration No. MR-8500053-0; "SCBSL"). Recipients in Singapore should contact SCBSL in relation to any matters arising from, or in connection with, this document. SCBSL is an indirect wholly-owned subsidiary of Standard Chartered Bank and is licensed to conduct banking business in Singapore under the Singapore Banking Act 1970. In Singapore, Standard Chartered Private Bank is the Private Banking division of SCBSL.

The products described in this document are not deposits and none of them qualifies as an insured deposit under the Deposit Insurance and Policy Owners' Protection Schemes Act 2011, or any other deposit protection scheme by any authority.

### SCBSL as distributor of the Fund and investment adviser to the investment manager of the Fund

SCBSL acts as a distributor of the Fund (which represents a proportion of all of the funds for which SCBSL acts as distributor) and investment adviser to the investment manager of the Fund. To the extent permitted under applicable law and regulations, SCBSL receives fees including trail commissions for the Fund that it distributes and investment adviser fees for the advisory services it provides to the investment manager in relation to the Fund. SCBSL, and/or a connected company, may at any time, to the extent permitted by applicable law and/or regulation, be invested in any securities, currencies or financial instruments referred to in this document or have a material interest in any such securities or related investment, or may be the only market maker in relation to such investments, or provide, or have provided advice, investment banking or other services, to issuers of such investments. Accordingly, SC, its affiliates and/or subsidiaries may have a conflict of interest that could affect the objectivity of this document.

#### Capacity

If you decide to invest in the Fund through SCBSL, SCBSL will, as distributor, be acting as agent for you only for the purpose of effecting transactions in relation to the Fund as directed by you. In no circumstances will SCBSL act as an investment adviser to you.

### Risks involved in investing in the Fund

You should not invest in the Fund unless you are satisfied that an investment in the Fund is suitable for you and you have fully understood the features and risk of investing in the Fund. The Fund may not be available for distribution to you depending on your location, domicile, nationality or the SC Entity you are dealing with. Please contact your Relationship Manager for more information. If you are resident or domiciled in countries/markets where fiscal or exchange control regulations may impinge on foreign or offshore investments, you should seek advice before proceeding.

You should read the relevant offering documents of the Fund carefully for detailed information before deciding whether to invest in the Fund and you should pay particular attention to the risk factors set out therein. We recommend that you seek independent professional advice that takes into account considerations such as your financial situation and risk tolerance before making any investment decisions. Do not invest in investment products unless you fully understand and are willing to assume the risks associated with them.

The Fund may invest extensively in financial derivatives instruments or emerging markets and may have leveraged exposure, which may lead to higher risk of capital loss. Please ensure that you are comfortable with the risks involved before making an investment.

#### Information purposes

This document is for information purposes only and its content is not from independent research. It is meant only for use as a reference tool. It has not been prepared for any particular person or category of persons.

The Fund referred herein constitutes only a portion of the funds that are available for distribution from SCBSL and references to the Fund in this document do not constitute recommendations over any other funds available from SCBSL.

Please note that the Investment Adviser's commentary contained in this document: (a) is the property of SC; (b) is not intended to provide financial, legal, accounting or tax advice to any person and should not be relied upon in that regard; (c) may not be copied or distributed without the prior consent of SC; and (d) is based on sources believed by SC to be reliable, although SCBSL does not make any representation or guarantee as to accuracy or completeness.

Information and data contained in this document are current only as at its date and may no longer be true or complete when read by an investor. Information and data contained herein are subject to change without notice to you. SC (for the avoidance of doubt, including SCBSL) accepts no liability and will not be liable for any loss or damage arising directly or indirectly (including special, incidental or consequential loss or damage) from your use of this document, howsoever arising, and including any loss, damage or expense arising from, but not limited to, any defect, error, imperfection, fault, mistake or inaccuracy with this document, its contents or associated services, or due to any unavailability of the document or any part thereof or any contents or associated services.

### Your independent investment decision

Any investment decision by you should not be made based solely on the information contained in this document and you accept that SC has no responsibility or obligation in connection with your decision to invest in the Fund referred to in this document.

### Market Abuse Regulation (MAR) Disclaimer

All investment materials provided by Amundi should be regarded as marketing or informational communications as they are based on non-independent research. They are not intended to be investment research and have not been prepared in accordance with legal requirements to promote the independence of investment research. The marketing and informational communications provided are solely for informational purposes and should not be regarded as a recommendation to buy, sell or otherwise deal in any particular investment. You should make your own independent evaluation of the relevancy and adequacy of the information contained in this document and seek independent professional advice to determine whether the Fund is suitable for you.



